Progress in the treatment of disseminated intravascular coagulation in patients with acute promyelocytic leukemia / 国际儿科学杂志

ABSTRACT

Acute promyelocytic leukemia ( APL) is identified as the M3 subtype of acute myelo-cytic leukemia ( AML) . One of its clinical features is severe coagulation dysfunction. Most patients could de-velop disseminated intravascular coagulation ( DIC) resulting vital viscera hemorrhage, which is one of the significant causes of early death in APL patients. Early diagnosis and inductive therapy, dynamic monitoring pa-tients' coagulation index and correcting the abnormal coagulation could prevent the occurrence or progress of DIC, and then improving the early-term survival rate of APL patients. At present, APL is mainly treated from the treatment of primary disease, anticoagulant antifibrinolytic therapy, and alternative therapy.